Please login to the form below

Not currently logged in
Email:
Password:

cost-effectiveness

This page shows the latest cost-effectiveness news and features for those working in and with pharma, biotech and healthcare.

Novartis’ MS therapy Mayzent approved by NICE

Novartis’ MS therapy Mayzent approved by NICE

Agency approves drug after new cost-effectiveness proposal. Novartis’ oral drug Mayzent has been recommended by the UK’s National Institute for Health and Care Excellence (NICE) for the treatment of ... The NICE committee concluded that ultimately

Latest news

  • NICE recommends Roche’s Polivy for B-cell lymphoma NICE recommends Roche’s Polivy for B-cell lymphoma

    Cost-effectiveness agency approves drug following initial rejection earlier this year. The UK’s National Institute for Health and and Care Excellence (NICE) has recommended the use of Roche’s antibody ... NICE said that the cost-effectiveness of the

  • NICE recommends Astellas’ Xospata for NHS use NICE recommends Astellas’ Xospata for NHS use

    Cost-effectiveness watchdog backtracks on previous rejection. The UK’s National Institute for Health and Care Excellence (NICE) has recommended Astellas’ Xospata for routine use on the NHS, backtracking on its ... The cost-effectiveness watchdog also

  • Biohaven gets FDA approval for migraine drug Nurtec ODT Biohaven gets FDA approval for migraine drug Nurtec ODT

    The loser in its assessment was Lilly, as it said the annual list price of $4, 610 for Reyvow was well in excess of its cost-effectiveness threshold and should be ... for clinical trials to support approval, as this almost doubled the cost-effectiveness

  • Celgene’s Revlimid scores NICE approval in follicular lymphoma Celgene’s Revlimid scores NICE approval in follicular lymphoma

    New ‘chemotherapy-free’ treatment for patients with limited options. Celgene has scored a positive recommendation from England’s cost-effectiveness watchdog NICE for Revlimid in follicular lymphoma, chalking up another indication

  • SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

    England’s cost-effectiveness watchdog NICE issued a positive recommendation for the drug back in  2018, not long after Crysvita was granted a conditional marketing authorisation from the European Medicines Agency.

More from news
Approximately 3 fully matching, plus 577 partially matching documents found.

Latest Intelligence

  • 2021: the year of decentralisation in drug development 2021: the year of decentralisation in drug development

    The end result will be improvements in trial speed, which will drive more novel therapies to patients faster and with greater cost efficiency. ... Implementing a robust and flexible monitoring strategy can increase efficiency and cost-effectiveness.

  • Growing evidence supports the important role of biosimilars in healthcare Growing evidence supports the important role of biosimilars in healthcare

    New data released at the ASCO Quality Care Symposium continues to underscore the cost-effectiveness of biosimilar treatment options in cancer care. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimer’s disease

    The cost burden. Payer opinion in AD has shown high levels of concern at the expected cost burden that new treatments and pathways could place on health systems. ... Yet NICE and many other HTA bodies limit their assessment to the cost-effectiveness of

  • It started with a miss It started with a miss

    for sustainability in healthcare systems.That has affected how launches work because people are looking for, and are now able to measure, different things from treatments – cost- effectiveness, societal value, whole ... In today’s marketplace, with

  • Evolution or revolution: the latest review of NICE methods Evolution or revolution: the latest review of NICE methods

    With details emerging on the latest review of the methods NICE uses to make cost-effectiveness recommendations, more change could be on the way, but will it be evolution or revolution? ... What is not part of the review – because it’s a done deal as

More from intelligence
Approximately 0 fully matching, plus 65 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 24 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics